Antimicrobial activity of carvacrol and its derivatives on Mycobacterium spp. : systematic review of preclinical studies
Background: The scope of the study was to analyze original preclinical studies on the antimicrobial effects of carvacrol and derivatives on the Mycobacterium genus. Materials & methods: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, four databases (PubMed, Web of Science, SCOPUS and EMBASE) were searched. Results: The search retrieved 392 records, of which 11 papers were selected. Heterogeneity in the techniques and mycobacterial targets was observed. Carvacrol demonstrated synergistic antimycobacterial activity with rifampicin against multidrug-resistant Mycobacterium tuberculosis on membranes and biofilms. In silico approaches showed specific targets in mycobacteria, by inhibition and molecular docking assays, on the enzyme chorismate mutase and the heat shock protein 16.3. Conclusion: Carvacrol has been shown to be a scaffold candidate for future molecules with activity against mycobacteria.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 16(2024), 7 vom: 23. März, Seite 679-688 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fermiano, Thiago H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9B1J4V995Q |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2023-0249 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368807436 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368807436 | ||
| 003 | DE-627 | ||
| 005 | 20240313234436.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2023-0249 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM368807436 | ||
| 035 | |a (NLM)38390753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fermiano, Thiago H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antimicrobial activity of carvacrol and its derivatives on Mycobacterium spp. |b systematic review of preclinical studies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: The scope of the study was to analyze original preclinical studies on the antimicrobial effects of carvacrol and derivatives on the Mycobacterium genus. Materials & methods: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, four databases (PubMed, Web of Science, SCOPUS and EMBASE) were searched. Results: The search retrieved 392 records, of which 11 papers were selected. Heterogeneity in the techniques and mycobacterial targets was observed. Carvacrol demonstrated synergistic antimycobacterial activity with rifampicin against multidrug-resistant Mycobacterium tuberculosis on membranes and biofilms. In silico approaches showed specific targets in mycobacteria, by inhibition and molecular docking assays, on the enzyme chorismate mutase and the heat shock protein 16.3. Conclusion: Carvacrol has been shown to be a scaffold candidate for future molecules with activity against mycobacteria | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a antibacterial agents | |
| 650 | 4 | |a carvacrol | |
| 650 | 4 | |a monoterpenes | |
| 650 | 4 | |a nontuberculous mycobacteria | |
| 650 | 4 | |a rifampicin | |
| 650 | 4 | |a tuberculosis | |
| 650 | 7 | |a carvacrol |2 NLM | |
| 650 | 7 | |a 9B1J4V995Q |2 NLM | |
| 650 | 7 | |a Cymenes |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Perez de Souza, João V |e verfasserin |4 aut | |
| 700 | 1 | |a Murase, Letícia S |e verfasserin |4 aut | |
| 700 | 1 | |a Salvaterra Pasquini, João P |e verfasserin |4 aut | |
| 700 | 1 | |a de Lima Scodro, Regiane B |e verfasserin |4 aut | |
| 700 | 1 | |a Zanetti Campanerut-Sá, Paula A |e verfasserin |4 aut | |
| 700 | 1 | |a Caleffi-Ferracioli, Katiany Rizzieri |e verfasserin |4 aut | |
| 700 | 1 | |a Dias Siqueira, Vera L |e verfasserin |4 aut | |
| 700 | 1 | |a Meneguello, Jean E |e verfasserin |4 aut | |
| 700 | 1 | |a Vieira Teixeira, Jorge J |e verfasserin |4 aut | |
| 700 | 1 | |a Cardoso, Rosilene Fressatti |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 16(2024), 7 vom: 23. März, Seite 679-688 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:7 |g day:23 |g month:03 |g pages:679-688 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2023-0249 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 7 |b 23 |c 03 |h 679-688 | ||